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Abstract
To investigate the mechanism how Transforming growth factor-β(TGF-β) represses Interleukin-1β
(IL-1β)-induced Proteinase-Activated Receptor-2 (PAR-2) expression in human primary synovial
cells (hPSCs). Human chondrocytes and hPSCs isolated from cartilages and synovium of
Osteoarthritis (OA) patients were cultured with 10% fetal bovine serum media or serum free
media before treatment with IL-1β, TGF-β1, or Connective tissue growth factor (CTGF). The
expression of PAR-2 was detected using reverse transcriptase-polymerase chain reaction (RT-
PCR) and western blotting. Collagen zymography was performed to assess the activity of Matrix
metalloproteinases-13 (MMP-13). It was demonstrated that IL-1β induces PAR-2 expression via
p38 pathway in hPSCs. This induction can be repressed by TGF-β and was observed to persist for
at least 48 hrs, suggesting that TGF-β inhibits PAR-2 expression through multiple pathways. First
of all, TGF-β was able to inhibit PAR-2 activity by inhibiting IL-1β-induced p38 signal transduction
and secondly the inhibition was also indirectly due to MMP-13 inactivation. Finally, TGF-β was able
to induce CTGF, and in turn CTGF represses PAR-2 expression by inhibiting IL-1β-induced
phospho-p38 level. TGF-β could prevent OA from progression with the anabolic ability to induce
CTGF production to maintain extracellular matrix (ECM) integrity and to down regulate PAR-2
expression, and the anti-catabolic ability to induce Tissue inhibitors of metalloproteinase-3 (TIMP-
3) production to inhibit MMPs leading to avoid PAR-2 over-expression. Because IL-1β-induced
PAR-2 expressed in hPSCs might play a significantly important role in early phase of OA, PAR-2
repression by exogenous TGF-β or other agents might be an ideal therapeutic target to prevent
OA from progression.
Background
Osteoarthritis (OA) is a degenerative disease characterized
by depletion of articular cartilage and formation of osteo-
phytes [1]. OA formed under the condition of imbalance
between anabolic and catabolic mediators, when catabo-
lism is greater than anabolism, the risk of OA raises. The
catabolic mediators include MMPs, ADAMTS, ADAM, IL-
1β, IL-17, IL-18 and TNF-α, which increase degradation of
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cartilage and inhibit synthesis of metalloproteinase inhib-
itors such as TIMPs, tenascin and YKL-40. The anabolic
mediators include TGF-β, IGF-1, FGFs and BMPs, which
stimulate synthesis and repairing of cartilage. The secreted
proinflammatory cytokines and metalloproteinases up-
regulate expression of chondrocyte PAR-2, stimulating
more secretion of proinflammatory cytokines and metal-
loproteinases to enhance inflammatory response [2,3]
and degradation of ECM components of cartilage tissue,
causing progressive loss of cartilage. Furthermore, frag-
ments of protein degradation, like fibronectin fragments
and collagen type II fragments, seem to play a role in
inducing degradation of cartilage [4,5] as well as stimulat-
ing chondrocytes to repair the matrix.
TGF-β, a prominent member of the TGF-β superfamily of
ligands which include TGF-β s and BMPs, is vital for the
homeostasis of numerous cellular functions, including
cell growth, differentiation, and apoptosis in a broad
spectrum of tissues [6]. TGF-β signals are propagated
through direct physical interactions with the extracellular
domain of essentially two transmembrane serine/threo-
nine kinase receptors (Tβ-RI and Tβ-RII), which transduce
a number of secondary signals, most notably Smads 2 and
3 as well as PI3-kinase and various members of the
mitogen activated protein kinase (MAPK) family [7-10].
CTGF, a member of CCN family, is a cysteine-rich matri-
cellular protein. Expression of this protein is potently
induced by TGF-β via Smad pathway. CTGF promotes
chondrocytes proliferation through p38 MAPK and differ-
entiation via p42/p44 MAPK. Thus, CTGF is important for
cell proliferation and matrix remodeling during chondro-
genesis and is a key regulator coupling ECM remodeling
[11]. Several studies have proved that CTGF can stimulate
the proliferation and expression of the cartilage pheno-
type by promoting type II collagen and aggrecan produc-
tion, but did not stimulate the terminal hypertrophy or
calcification of articular cartilage cells, suggesting that
CTGF might be useful in the repair of damaged articular
cartilage [12-14]. Other report suggested that TGF-β
antagonizes IL-1β-mediated inflammation via decreasing
its receptor expression on chondrocytes [15-17] and TGF-
β and CTGF play a critical role in cartilage matrix repair-
ing; in addition, TGF-β is an anabolic and anti-catabolic
factor of articular cartilage.
PARs are a family of four G-protein-coupled receptors
which included four members: PAR-1, PAR-2, PAR-3, and
PAR-4 [18]. Among PARs, PAR-2 is unique in that it is acti-
vated by trypsin and mast cell tryptase, but not by
thrombin which activates the other three members of the
PAR family. This study focuses on PAR-2, which plays an
important role in inflammation and pain. Trypsin cleaves
PAR-2 at R34↓S35LIGKV of the extracellular N-terminus to
expose the hexameric tethered peptide that binds to con-
served regions in extracellular second loop of the receptor
to initiate signaling. During activation, PAR-2 couples to
Gα q/11, resulting in activation of phospholipase C-β,
production of inositol 1,4,5-trisphosphate and diacylglyc-
erol, and then activation of protein kinase C. In addition,
PAR-2 can activate ERK1/2 MAPK, mediating cell prolifer-
ation [11]. Recently, it was reported that PAR-2 was
expressed on chondrocytes and synovial cells and it was
overexpressed on osteoarthritic chondrocytes. The expres-
sion level of PAR-2 on chondrocytes is up-regulated by IL-
1β and TNF-α but down-regulated by TGF-β[12].
In human chondrocytes, a recent study has reported that
TGF-β induced TIMP-3 via PI3K/Akt signaling pathway
[19]. Several models have been proposed to explain how
TGF-β may activate the PI3K/Akt pathway. A recent study
further suggests that Tβ-RI associates with the p85 regula-
tory subunit of PI3K, thus enabling activation of the
p110α catalytic subunit of PI3K [6]. In this study, we aim
to study the mechanism how TGF-β represses IL-1β-
induced PAR-2 expression in human primary synovial
cells (hPSCs). Our findings emphasize that TGF-β
represses IL-1β-induced PAR-2 expression via multiple
pathways including TGF-β directly inhibits IL-1β induced
p-p38 level; TGF-β represses human synovial PAR-2 via
Akt-TIMP3-MMP13 pathway; TGF-β induces CTGF forma-
tion, and then CTGF reduces PAR-2 protein level in
hPSCs.
Materials and methods
Isolation and culture of human primary chondrocytes and 
synovial cells (hPSC)
Joint tissues were obtained from patients with OA under-
going implant surgery for total knee replacement. Articu-
lar tissues was surgically removed and separated from
adjacent non-lesional tissues that appeared to be morpho-
logically normal. Chondrocytes and synovial cells from
those specimens were isolated as described. Briefly, tissues
specimens were first cut into pieces (2~3 mm3), and
chondrocytes and synovial cells were released from the
articular tissues by sequential incubation with 1 mg/mL
hyaluronidase (Sigma Chemical St. Louis, Mo, USA) for
15 min, 0.25% proteinase for 30 min, and 2 mg/mL type
II collagenase (Sigma) for 12 h at 37°C in Dulbecco's
modified Eagle medium (DMEM) (Gibco BRL, Life Tech-
nologies, Grand Island, NY, USA). After isolation,
chondrocytes and synovial cells were resuspended in
DMEM containing 10% FBS and 1% L-glutamine, and
then incubated at 37°C in a humidified atmosphere with
5% CO2 and 95% air. All experiments of cell starvation
were intended to render quiescent.Journal of Biomedical Science 2009, 16:97 http://www.jbiomedsci.com/content/16/1/97
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Reverse-transcription polymerase chain reaction (RT-
PCR)
The extracted RNA (2 μg) was reverse-transcribed at 37°C
for 1.5 h by adding 5 μM of random hexamer oligonucle-
otides (Gibco BRL, Life Technologies, Grand Island, NY,
USA), 200 units of reverse transcriptase (Takara Bio Inc.,
Japan), 2.5 mM deoxyribonucleotide triphosphate
(dNTP) (Takara Bio.), and 10 mM dithiothreitol. PCR
primers for amplification of MMP-1, MMP-3, MMP-13,
IL-8, and GAPDH cDNA were synthesized according to
the following oligonucleotide sequences. CTGF: Sense, 5'
CCG TAC TCC CAA AAT CTC CA, Anti-sense, 5' GTA ATG
GCA GGC ACA GGT CT; PAR-1: Sense, 5'ACC ACA TTT
GCT CCA TCC TC, Anti-sense, 5' CCT ATT GGA GTG CCC
ACA GT; PAR-2: Sense, 5' CTG CCT ATG TGC TGA T, Anti-
sense, 5' CGG ACA CTT CGG CAA A; PAR-3: Sense, 5'ACC
CTC CAC CAC TTC ACA AG, Anti-sense, 5'AGC AAG AGG
TTT GGT TGG TG; PAR-4: Sense, 5'GTG GGC CTT ACA
TCC AGT GT, Anti-sense, 5'CCT TCT GCC TCA GTC TCC
TG; TIMP-3: Sense, 5'CCT TCT GCC TCA GTC TCC TG,
Anti-sense, 5' AAG AAG CCT CTA CCC CCA AA; GAPDH:
Sense, 5'CAA GGC TGA GAA CGG GAA GC, Anti-sense,
5'AGG GGG CAG AGA TGA TGA CC. PCR was carried out
with 2 μl of template cDNA and 23 μl of PCR mix buffer
containing each primer (0.2 μM), dNTP (2.5 mM), and
Taq DNA polymerase (1.25 units) (Takara Bio.). After the
PCR, 15 μl of the reaction mixture was subjected to elec-
trophoresis on a 1.5% agarose gel, and the PCR products
were visualized by ethidium bromide staining. The levels
of mRNA for MMPs and GAPDH were quantified by scan-
ning densitometry (Image-Pro Plus, Media Cybernetics,
MD, USA). Equal loading of DNA samples in each lane
was indicated by equal intensity of internal control,
GAPDH. The data shown here are representative of three
independent experiments.
Western blot analysis
Cells were extracted from the total protein using ice-cold
RIPA lysis buffer (10 mM Tris-HCl (pH 7.6), 158 mM
NaCl, 1.0 mM EDTA, 0.1% SDS, 1% Triton X-100, 1.0 mg/
ml leupeptin, 1.0 mg/ml aprotinin, and 0.5 mM PMSF).
The lysates were transferred to Eppendorf tubes and cen-
trifuged at 14,000 rpm for 30 min at 4°C. The superna-
tants were transferred to fresh tubes, and the protein
concentration was determined using the Bio-Rad Protein
assay. Similar amounts of protein were separated by 10%
SDS-PAGE and transferred to a nitrocellulose membrane
(Gelman, Ann Arbor, MI, USA) by electroblotting. The
membrane was blocked overnight in a 5% milk powder/
TBST solution and then further incubated with one of the
following antibodies (Abs): MMP-1, -3, or -13 Ab (Onco-
gene, Merck, Taipei, Taiwan) for 2 h. Membranes were
washed three times with TBST, then further incubated
with the appropriate HRP-labeled secondary Ab in 5%
milk powder/TBST, and developed using an ECL system
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). Equal
loading of protein samples in each lane was indicated by
equal intensity of loading control protein, GAPDH. The
data shown here are representative of three independent
experiments.
Collagen zymography
To analyze MMP-13 activities, concentrated media were
mixed with sample buffer without reducing agent or boil-
ing. The sample was loaded into 0.5 mg/ml collagen-con-
taining SDS-polyacrylamide gel, and then undergoing
electrophoresis. After electrophoresis, remove SDS from
the gel by washing in 2.5% Triton X-100 solution for 30
minutes at room temperature that allows enzymes to reac-
tivate and degrade the protein substrate. Then, the gel was
rinsed with developing buffer containing 25 mM Tris-
HCl, 0.2 M NaCl, 6 mM CaCl2, and 0.02% Brij for 30 min-
utes at room temperature and then incubation with devel-
oping buffer at 37°C overnight. Afterward, zymographic
activities were revealed by staining with 0.5% CBB R-250
(Sigma) for 30 minutes at room temperature and destain-
ing with CBB destainer.
Statistical analysis
Results were normalized to the copy numbers of GAPDH
or α-tubulin. The mean and standard deviation were used
to evaluate the mRNA and protein level of CTGF, PAR-2,
and TIMP-3. Student's t test was used for comparison of
the difference in expression level of target proteins and
target gene between samples within the same set. The
effects of the first stimulation were done as positive con-
trol and were analyzed as changes relative to un-stimu-
lated baseline, using repeated measure analysis of
variance, and the inhibitory effects of the second drug co-
treated with the first stimulant were analyzed as relative to
positive control by using repeated measurement of vari-
ance. These analyses were performed individually and for
the group as a whole. Statistical significance was set as *:
P < 0.05 and **: P < 0.01 comparing to basal control and
$: P < 0.05 and $$: P < 0.01 comparing to positive control.
Results
Induction of PAR-1, PAR-2, PAR-3, and PAR-4 mRNA level 
by IL-1β in hPSCs and chondrocytes
hPSCs and chondrocytes were incubated with 10 ng/ml of
IL-1β in serum-free DMEM for 30, 60, and 90 minutes fol-
lowing 24 hours of starvation. Results shown by Fig. 1A
demonstrates that the mRNA levels of PAR-1, PAR-2, and
PAR-3 were significantly induced by IL-1β in human
chondrocytes, but only PAR-2 mRNA was up-regulated by
IL-1β in human primary synovial cell. In addition, PAR-2
had higher expression level in hPSCs than that in human
chondrocytes, which suggests that PAR-2 in hPSCs might
play a more significant role in the progression of OA.Journal of Biomedical Science 2009, 16:97 http://www.jbiomedsci.com/content/16/1/97
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Induction of PAR-1, PAR-2, PAR-3, and PAR-4 mRNA level by IL-1β in hPSCs and chondrocytes and Induction of PAR-2  mRNA and protein level by IL-1β in hPSCs Figure 1
Induction of PAR-1, PAR-2, PAR-3, and PAR-4 mRNA level by IL-1β in hPSCs and chondrocytes and Induction 
of PAR-2 mRNA and protein level by IL-1β in hPSCs. (A). hPSCs and chondrocytes were incubated in 10 ng/ml of IL-1β 
in serum-free DMEM for 30, 60, and 90 minutes following 24 hours of starvation and PAR-1, PAR-2, PAR-3, and PAR-4 mRNA 
level of hPSCs and chondrocytes were determined by RT-PCR (n = 3). Lane 1 as basal control and lane 2 to lane 4 were com-
pared with basal control. (B). hPSCs were incubated in 10 ng/ml of IL-1β in serum-free DMEM for 30, 60, and 90 minutes fol-
lowing 24 hours of starvation (n = 3). hPSCs were incubated with 10 ng/ml of IL-1β for 12, 24, and 48 hours (n = 3). Lane 1 as 
basal control and lane 2 to lane 4 were compared with basal control.Journal of Biomedical Science 2009, 16:97 http://www.jbiomedsci.com/content/16/1/97
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Induction of PAR-2 mRNA and protein level by IL-1β in 
hPSCs
For inducing PAR-2 mRNA expression, hPSCs were treated
with 10 ng/ml of IL-1β for 30, 60, and 90 minutes, while
PAR-2 protein level after treatment with 10 ng/ml of IL-1β
was determined at 12, 24, and 48 hrs. As shown by Fig. 1B,
IL-1  β induced mRNA expression of PAR-2 in hPSCs
started at 30 minute and reached maximal effect at the
time point of 1 hr (Fig. 1B, mRNA level). IL-1 β induced
PAR-2 protein expression at 12 hr that elevated up to 48
hr (Fig. 1B, protein level).
Inhibition of IL-1β-induced PAR-2 expression by p38 
MAPK inhibitor but not by MEK or JNK MAPK inhibitor in 
hPSCs
In order to elucidate the pathways by which hPSCs regu-
late PAR-2 level by IL-1β, MAPK inhibitors were pre-
treated for 1 hr followed by stimulating with IL-1β for 12
hrs, and PAR-2 protein level was determined. As shown by
Fig. 2A, SB202190, a p38 inhibitor, significantly inhibited
IL-1β induced PAR-2 expression of protein level which
was not inhibited by U0126, a MEK inhibitor or
SP600125, a JNK inhibitor.
TGF-β1 suppresses excess expression PAR-2 induced by IL-
1β in hPSCs
According to a recent report, TGF-β can decrease over-
expressed PAR-2 protein levels of chondrocytes from OA
patients, but this phenomenon has not been observed in
chondrocytes from non-OA patients that expressed nor-
mal PAR-2 level [2]. These results suggest that TGF-β is a
regulator of PAR-2 expression in human chondrocytes. In
light of this, the hPSCs were pre-treated with IL-1β for 30
minutes to mimic early OA condition to increase PAR-2
protein level, and then co-treated with various concentra-
tions of TGF-β1 for 12 hrs or co-treated with 10 ng/ml of
TGF-β1 for 12, 24, and 48 hrs. As shown by Fig. 2B and
2C, increasing PAR-2 protein level induced by IL-1β could
be down-regulated by TGF-β1 in a dose-dependent (Fig.
2B) and a time-dependent manner from 12 to 48 hrs (Fig.
2C).
TGF-β1 inhibits IL-1β mediated p38 MAPK activation, but 
not JNK or ERK level of hPSCs
It was demonstrated as above that IL-1β induced PAR-2
expression of hPSCs via p38 MAPK pathway and TGF-β1
could reduce this induction of PAR-2 expression. Since
that, the mechanisms by which TGF-β1 inhibits IL-1β-
mediated PAR-2 expression in hPSCs were investigated.
Cells were pre-treated with IL-1β for 30 minutes to mimic
OA condition, followed by co-treating with TGF-β1 for
various time periods from 15 to 60 minutes and then p-
p38, p-ERK, and p-JNK level were analyzed. As shown by
Fig. 3, TGF-β1 reduced IL-1β mediated p-p38 level, at the
time points of 15, 30, and 60 minutes, but TGF-β1 had no
inhibition effect on p-ERK or p-JNK levels.
TGF-β1 induces mRNA and protein expression level of 
CTGF in hPSCs
TGF-β1 was reported to be a strong inducer of CTGF in
many cell types, such as fibroblast, hepatocytes, renal
cells, and keratinocytes [20]. The effect of treating hPSCs
with different dosage of TGF-β1 for 6 hrs on CTGF mRNA
level was investigated. As shown by Fig. 4A, TGF-β1
induced CTGF mRNA expression following a dose-
dependent pattern. Then treatments with 10 ng/ml of
TGF-β1 for 12, 24, and 48 hrs or various concentration of
TGF-β1 for 24 hrs were conducted, CTGF protein levels in
both cellular and medium were determined. As shown by
Fig. 4B, TGF-β1 induced CTGF production in a time-
dependent manner after 12 hrs treatment and persisted to
at least 48 hrs. TGF-β1 induced CTGF production also fol-
lowed a dose-dependent manner after 24 hrs treatment as
demonstrated by Fig. 4C.
CTGF suppresses PAR-2 protein level induced by IL-1β in 
hPSCs
Since CTGF has been hypothesized as the major down-
stream mediator of TGF-β1 [20], it was wondered if inhi-
bition of PAR-2 expression by TGF-β1 in hPSCs not only
via direct inhibition of p38 signal pathway, but also
through the induction of CTGF which could further
reduce PAR-2 protein level. The hPSCs were pre-treated
with 10 ng/ml of IL-1β for 30 minutes, followed by treat-
ing with 50 ng/ml of CTGF for 12 and 24 hrs [21,22], after
then cellular PAR-2 protein level was determined. As
shown by Fig. 4D, CTGF repressed IL-1β-induced PAR-2
protein level after 24 hrs of treatment.
CTGF inhibits IL-1β-mediated p38 MAPK activation, but 
activated ERK pathway of hPSCs
CTGF is an anabolic factor in OA process because this fac-
tor stimulates cell proliferation and ECM marker produc-
tion, such as type II collagen and aggrecan in human
chondrocytes [21,22]. CTGF was known as well to interact
with TGF-β to deliver TGF-β to TGFRII [20], so it can
enhance TGF-β activity. In light of this, it was thought that
CTGF might enhance TGF-β-mediated p38 inhibition on
the PAR-2 expression. To prove hypothesis, the hPSCs
were treated with 50 ng/ml of CTGF for 15, 30, and 60
minutes following the exposure to 10 ng/ml of IL-1β, after
then p-p38 level was determined. As shown by Fig. 5,
CTGF inhibited IL-1β induced p-p38 level but not p-ERK
or p-JNK level after 30 minutes of treatment (Fig. 5A),
while treatment with CTGF alone does not affect p-p38
level of hPSCs (Fig. 5B). In order to validate that TGF-β
inhibits p-p38 is mediated by CTGF-TGF-β interaction, p-
p38 inhibition effect among treatments with TGF-β1,
CTGF, and combination of both were compared. AsJournal of Biomedical Science 2009, 16:97 http://www.jbiomedsci.com/content/16/1/97
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Figure 2 (see legend on next page)Journal of Biomedical Science 2009, 16:97 http://www.jbiomedsci.com/content/16/1/97
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Inhibition of IL-1β-induced PAR-2 expression by p38 MAPK inhibitor but not by MEK or JNK MAPK inhibitor and TGF-β1 sup- presses PAR-2 protein level induced by IL-1β in hPSCs Figure 2 (see previous page)
Inhibition of IL-1β-induced PAR-2 expression by p38 MAPK inhibitor but not by MEK or JNK MAPK inhibitor 
and TGF-β1 suppresses PAR-2 protein level induced by IL-1β in hPSCs. (A) hPSCs were pre-treated with 5 μM of 
U0126, SP600125, and SB202190 in serum-free DMEM for 1 hour and then incubated with 10 ng/ml of IL-1β for 12 hours in 
serum-free DMEM (n = 3). Lane 1 as basal control and lane 2 as positive control, lane 3 to lane 5 were compared with positive 
control. (B) hPSCs were pre-treated with 10 ng/ml of IL-1β in serum-free DMEM for 30 minutes and then incubated with 2, 5, 
10, and 30 ng/ml of TGF-β1 in serum-free DMEM for 12 hours (n = 3). Lane 1 as basal control and lane 2 as positive control, 
lane 3 to lane 6 were compared with basal control. (C) hPSCs were pre-treated with 10 ng/ml of IL-1β in serum-free DMEM 
for 30 minutes and then incubated with 10 ng/ml of TGF-β1 for 12, 24, and 48 hours in serum-free DMEM (n = 3). Lane 1 as 
basal control and lane 2, 4, and 6 as positive controls of lane 3, 5, and 7. Lane 2, 4, and 6, were compared with basal control; 
lane 3 was compared with lane 2; Lane 5 was compared with lane 4; and lane 7 was compared with lane 6.
TGF-β1 inhibits IL-1β-mediated p38 MAPK activation, but not JNK or ERK level Figure 3
TGF-β1 inhibits IL-1β-mediated p38 MAPK activation, but not JNK or ERK level. hPSCs were first incubated in 
serum-free DMEM for 24 hours and then pre-treated with 10 ng/ml of IL-1β in serum-free DMEM for 30 minutes and then 
incubated with 10 ng/ml of TGF-β1 for 15, 30, and 60 minutes in serum-free DMEM (n = 3). Lane 1 as basal control and lane 2, 
4, and 6 as positive controls of lane 3, 5, and 7. Lane 2, 4, and 6, were compared with basal control; lane 3 was compared with 
lane 2; Lane 5 was compared with lane 4; and lane 7 was compared with lane 6.Journal of Biomedical Science 2009, 16:97 http://www.jbiomedsci.com/content/16/1/97
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Figure 4 (see legend on next page)Journal of Biomedical Science 2009, 16:97 http://www.jbiomedsci.com/content/16/1/97
Page 9 of 14
(page number not for citation purposes)
shown by Fig. 5C, when combined treatment with both of
TGF-β1 and CTGF demonstrates a greater p-p38 inhibi-
tion effect than that treated with TGF-β1 or CTGF alone.
TGF-β1 up-regulates mRNA and protein level of TIMP-3 in 
hPSCs
It was reported that TGF-β1 can reduce MMPs level in
human chondrocytes due to its ability to induce TIMP-3,
a nature inhibitor of MMPs in vivo [23]. Therefore,
whether or not TGF-β can induce TIMP-3 production in
hPSCs was investigated. After treatment with 10 ng/ml of
TGF-β1 in a time course, the protein and mRNA levels of
TIMP-3 in the hPSCs were determined. As shown by Fig.
6, TIMP-3 mRNA level was induced by TGF-β1 after 1 hr
treatment and had greater effect at the time point of 4 hr
(Fig. 6A). TGF-β1 also induced TIMP-3 protein expression
followed a time-dependent manner during 6 to 24 hrs
after treatment (Fig. 6B).
TGF-β1 induces TIMP-3 expression via Akt pathway in 
hPSCs
It has been reported that TGF-β1 induced TIMP-3 expres-
sion through Akt pathway in human chondrocytes [23]. If
this induction through the same pathway in hPSCs was
then determined. hPSCs were treated with 10 ng/ml of
TGF-β1 for various time periods from 15 to 240 minutes
and then p-Akt level was analyzed. As shown by Fig. 6,
TGF-β1 induced p-Akt level after 120 minutes of treat-
ment and this induction persisted at least 240 minutes
(Fig. 6C). To further confirm it, the cells were pre-treated
with SH-6, an inhibitor of Akt, for 30 minutes, and then
10 ng/ml of TGF-β1 was added and TIMP-3 mRNA and
protein level were analyzed at the time point of 4 hr and
24 hr. As shown by Figs. 6D and 6E, SH-6 almost blocked
total TGF-β1-induced TIMP-3 mRNA and protein expres-
sion, respectively.
TIMP-3 blocks MMP-13 activity in culture medium of 
hPSCs
It is known that TIMP-3 inhibits MMP-13 by competing
the catalytic pocket of MMP-13 with its substrate, colla-
gen. MMP-13 activity was examined in culture medium of
hPSCs to confirm that TIMP-3 functioned. The cells were
pre-treated with 10 ng/ml of IL-1β for 12 hrs to induce
MMP-13 secretion, and then those were co-treated with
10 ng/ml of TGF-β1 for 12 hrs to induce TIMP-3 produc-
tion and then MMP-13 activity was investigated in condi-
tioned medium by collagen zymography. As shown by
Fig. 7A, MMP-13 activity was significantly induced by IL-
1β, but when the cells were treated with TGF-β1, TIMP-3
was produced and subsequently MMP-13 activity was
blocked.
Blocking of MMP-13 function resulted in down-regulation 
of PAR-2 protein level of hPSCs
It was observed that suppression of MMP-13 activity also
reduced PAR-2 protein level in human chondrocytes. It
was because that inhibition of MMP-13 could slow down
cartilage break and then reducing stimulating factor for
proinflammatory cytokines releasing. As a result, inhibi-
tion of MMP-13 function leads to reduce PAR-2 expres-
sion indirectly. Based on the reported study that
concentration of MMP-13 in synovial fluid of OA patients
lies in the range of 0.1~1.5 ng/ml [24], hPSCs were treated
with various concentrations of MMP-13 in this range for
24 hrs and then cellular PAR-2 protein level was deter-
mined. As shown by Fig. 7B, the cells treated with the
higher concentration of MMP-13, the higher protein level
of PAR-2 was expressed, but vice versa.
Discussion
This study is the first report to demonstrate the pathway
how PAR-2 is repressed by TGF-β in hPSCs. According to
available reports [2], we know that PAR-2 is unique in its
distribution property because PAR-2 is the only member
of this family expressed in human chondrocytes. In con-
trast, hPSCs express PAR-1, PAR-2, and PAR-3. But in our
study, it was observed that PAR-1, PAR-2, and PAR-3 are
expressed in both human chondrocytes and hPSCs. Nev-
ertheless, we found that the mRNA levels of PAR-1, PAR-
2, and PAR-3 were significantly induced by IL-1β in
human chondrocytes, but only PAR-2 mRNA was up-reg-
TGF-β1 induces CTGF mRNA and protein expression level of hPSCs and CTGF suppresses PAR-2 protein level induced by IL- 1β in hPSCs Figure 4 (see previous page)
TGF-β1 induces CTGF mRNA and protein expression level of hPSCs and CTGF suppresses PAR-2 protein 
level induced by IL-1β in hPSCs. (A) hPSCs were incubated with 1, 2, 5, 10, and 30 ng/ml of TGF-β1 for 6 hours in serum-
free DMEM following 24 hours of starvation (n = 3). Lane 1 as basal control and lane 2 to lane 6 were compared with basal 
control. (B) hPSCs were incubated in 10 ng/ml of TGF-β1 in serum-free DMEM for 12, 24, and 48 hours. TGF-β1 significantly 
induced cellular and medium CTGF protein level after 12, 24, and 48 hours (n = 3). Lane 1 as basal control and lane 2 to lane 4 
were compared with basal control. (C) hPSCs were incubated with 1, 2, 5, 10, and 30 ng/ml of TGF-β1 for 24 hours in serum-
free DMEM. TGF-β1 significantly induced cellular and medium CTGF protein level when treated with 1, 2, 5, 10, and 30 ng/ml 
of TGF-β1 (n = 3). Lane 1 as basal control and lane 2 to lane 6 were compared with basal control. (D) hPSCs were pre-treated 
with 10 ng/ml of IL-1β in serum-free DMEM for 30 minutes and then incubated in 50 ng/ml of CTGF for 12 and 24 hours in 
serum-free DMEM (n = 3). Lane 1 as basal control and lane 2 and lane 4 as positive controls of lane 3 and 5. Lane 2 and 4 were 
compared with basal control; lane 3 was compared with lane 2 and Lane 5 was compared with lane 4.Journal of Biomedical Science 2009, 16:97 http://www.jbiomedsci.com/content/16/1/97
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CTGF inhibits IL-1β-mediated p38 MAPK activation, but activate ERK pathway of hPSCs Figure 5
CTGF inhibits IL-1β-mediated p38 MAPK activation, but activate ERK pathway of hPSCs. (A) hPSCs were first 
incubated in serum-free DMEM for 24 hours and then pre-treated with 10 ng/ml of IL-1β in serum-free DMEM for 30 minutes 
and then incubated with 50 ng/ml of CTGF for 15, 30, and 60 minutes in serum-free DMEM (n = 3). Lane 1 as basal control and 
lane 2, 4, and 6 as positive controls of lane 3, 5, and 7. Lane 2, 4, and 6, were compared with basal control; lane 3 was com-
pared with lane 2; Lane 5 was compared with lane 4; and lane 7 was compared with lane 6. (B) hPSCs were first incubated in 
serum-free DMEM for 24 hours and then pre-treated with 10 ng/ml of IL-1β in serum-free DMEM for 30 minutes and then 
incubated with 50 ng/ml of CTGF for 30 minutes in serum-free DMEM (n = 3). Lane 1 as basal control and lane 2 as positive 
control, lane 3 was compared with positive control and lane 4 was compared with basal control. (C) hPSCs were first incu-
bated in serum-free DMEM for 24 hours and then pre-treated with 10 ng/ml of IL-1β in serum-free DMEM for 30 minutes and 
then treated with 10 ng/ml of TGF-β1 or 50 ng/ml of CTGF alone or combined for 30 minutes in serum-free DMEM (n = 3). 
Lane 1 as basal control and lane 2 as positive control, lane 3 to lane 5 was compared with positive control.Journal of Biomedical Science 2009, 16:97 http://www.jbiomedsci.com/content/16/1/97
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ulated by IL-1β in hPSCs. In addition, PAR-2 had higher
expression level in hPSCs than that in human chondro-
cytes, which suggests that PAR-2 expression level in hPSCs
might play a more significant role in the progression of
OA.
PAR-1 is related with chemokine release, while PAR-2 is
directly related with inflammation [18]. It is possible that
during early phase of OA, IL-1β stimulates PAR-2 express-
ing by hPSCs via autocrine pathway and results more IL-
1β being secreted to up-regulate PAR-1 of human
chondrocytes and stimulating chemokine such as IL-6, IL-
8, eotaxin and MCP-1 releasing by human chondrocytes
that enhances OA severity.
In hPSCs, IL-1β up-regulated PAR-2 gene expression in
short time (Fig. 1B, mRNA level), suggesting that PAR-2
expression mainly occurs in the early phase of acute
inflammation. However, induction of PAR-2 protein level
by IL-1β was from 12 to 48 hrs in hPSCs (Fig. 1B, protein
level), suggesting that PAR2-mediated inflammatory
response in OA synovial cells through an amplification
effect.
Results showed that TGF-β inhibited PAR-2 protein level
induced by IL-1β followed a time dependent manner (Fig.
2C). This inhibition effect persisted for at least 48 hrs, sug-
gesting that TGF-β might inhibit IL-1β induced PAR-2
through multiple pathways. It was proved in this study
that TGF-β inhibits PAR-2 expression in hPSCs through
three pathways: by directly inhibition on p38 phosphor-
ylation, by inducing TIMP-3 which in turn results MMP-
13 dysfunction to ease inflammation cascade, and by
induction CTGF to block p38 signal pathway leading to
inhibit the proliferation of inflammatory cells.
It was seen that TGF-β inhibited p-p38 pathway, the major
signal pathway which mediated PAR-2 expression by
hPSCs (Fig. 2A), soon after 15 minutes of treatment (Fig.
3). This is the first mechanism of TGF-β suppressed PAR-
2 which occurred at the time point of 12 to 24 hrs as
observed by Fig. 2C.
Figure 6
TGF-β1 up-regulates mRNA and protein level of TIMP-3 in  hPSCs and TGF-β1 induces TIMP-3 expression via Akt path- way in hPSCs Figure 6
TGF-β1 up-regulates mRNA and protein level of 
TIMP-3 in hPSCs and TGF-β1 induces TIMP-3 
expression via Akt pathway in hPSCs. (A) hPSCs were 
incubated with 10 ng/ml of TGF-β1 in serum-free DMEM for 
1, 2, 4, and 6 hours following starvation for 24 hours. TIMP-3 
mRNA was significantly up-regulated after 1, 2, 4, and 6 
hours and had the maximal effect in the time of 4th hour (n = 
3). Lane 1 as basal control and lane 2 to lane 5 were com-
pared with basal control. (B) hPSCs were incubated with 10 
ng/ml of TGF-β1 in serum-free DMEM for 6, 12, and 24 
hours. TIMP-3 protein was significantly induced after 6, 12, 
and 24 hours (n = 3). Lane 1 as basal control and lane 2 to 
lane 4 were compared with basal control. (C) hPSCs were 
incubated in starvation medium for 24 hours and then 
treated with 10 ng/ml of TGF-β1 in serum-free DMEM for 
15, 30, 60, 120, and 240 minutes (n = 3). Lane 1 as basal con-
trol and lane 2 to lane 6 were compared with basal control. 
(D) hPSCs were incubated in starvation medium for 24 
hours and then treated with 10 μM of SH-6 for 30 minutes 
followed by incubated with 10 ng/ml of TGF-β1 in serum-free 
DMEM for 4 hours (n = 3). Lane 1 as basal control and lane 2 
as positive control, lane 3 was compared with positive con-
trol. (E) hPSCs were treated with 10 μM of SH-6 for 30 min-
utes followed by incubated with 10 ng/ml of TGF-β1 in 
serum-free DMEM for 24 hours (n = 3). Lane 1 as basal con-
trol and lane 2 as positive control, lane 3 was compared with 
positive control.Journal of Biomedical Science 2009, 16:97 http://www.jbiomedsci.com/content/16/1/97
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It should be noticed that PAR-2 was up-regulated under
the exposure to higher MMP-13 concentration for 24 hrs
in hPSCs (Fig. 7B). This might be due to higher MMP-13
concentration further enhanced inflammatory response
of synovial cells to stimulate IL-1β secretion. It was con-
sidered that up-regulation of PAR-2 by MMPs might be
indirectly. Hence, blocking MMP-13 can also prevent
over-expression of PAR-2. Besides direct inhibition of p38
signal pathway, TGF-β might inhibit PAR-2 through TGF-
β-TIMP-MMP-PAR2 cascade. According to our studies,
TIMP-3 protein was significantly induced by TGF-β after 6
to 24 hrs of treatment (Fig. 6B) to block MMP-13. Once
MMP-13 was blocked, PAR-2 level decreased within 24
hrs (Fig. 7B). In brief, inhibition of PAR-2 expression by
TGFβ-TIMP-MMP-PAR2 cascade lies during the time
period of 24 to 36 hr.
It was observed that CTGF activated ERK but inhibited
p38 pathway induced by IL-1β (Fig. 5A and Fig. 5B) in
hPSCs, of which was different for CTGF in human
chondrocytes which activated both ERK and p38 pathway
[20]. As reported, CTGF stimulates proliferation via p38
MAPK resulting in chondrocytes growth and differentia-
tion through p42/p44 MAPK pathway resulting in ECM
TIMP-3 blocks MMP-13 activity and blocking of MMP-13 function results in down-regulation of PAR-2 protein level of hPSCs Figure 7
TIMP-3 blocks MMP-13 activity and blocking of MMP-13 function results in down-regulation of PAR-2 protein 
level of hPSCs. (A) hPSCs were incubated with 10 ng/ml of IL-1β in serum-free DMEM for 12 hours and then co-incubated 
with 10 ng/ml of TGF-β1 in serum-free DMEM for 12 hours (n = 3). Lane 1 as basal control and lane 2 as positive control, lane 
3 was compared with positive control. (B) hPSCs were incubated with 2, 1, 0.5, and 0.1 ng/ml of MMP-13 in serum-free DMEM 
for 24 hours (n = 3). Lane 1 as basal control and lane 2 to lane 5 were compared with basal control.Journal of Biomedical Science 2009, 16:97 http://www.jbiomedsci.com/content/16/1/97
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specific marker expression. In contrast, CTGF activated
p42/p44 rather than p38 in hPSCs, suggesting that CTGF
mediates differentiation and ECM specific marker expres-
sion (data not shown) via p42/p44 pathway but not via
p38 pathway (Fig. 5A and Fig. 5B). This might be the rea-
son explained that over-expression of CTGF in human
chondrocytes results in osteophyte formation but over-
expression of CTGF in hPSCs does not lead to osteophyte
formation.
It is noticeable that CTGF enhanced TGF-β-mediated p38
inhibition in hPSC (Fig. 5C). This suggests that TGF-β
inhibits p38 through CTGF and CTGF enhances TGF-β
activity by presenting TGF-β to TGFR [20]. So, another
pathway that TGF-β inhibits p38 is by inducing CTGF to
reduce phospho-p38 level. It was observed that TGF-β sig-
nificantly induced CTGF protein level after 12 to 48 hrs
(Fig. 4B) and then PAR-2 was repressed by CTGF after 24
hrs (Fig. 4D). It was concluded that the inhibition of p38
induced by IL-1β via TGF-β-CTGF-p38 cascade occurs dur-
ing the time period of 36 to 48 hr.
In conclusion, this study suggests that TGF-β inhibits IL-
1β induced PAR-2 expression level through three pathway
at various time points. First, TGF-β directly inhibits IL-1β
induced p-p38 level within 24 hrs. Secondary, TGF-β
induces TIMP-3 expression resulting in suppression of
MMP-13 function, leading that PAR-2 over-expression
being eased off by TGF-β-TIMP3-MMP13 cascade occurs
during the time period of 24 to 36 hr. Finally, TGF-β
induces CTGF formation after 12 hrs, and CTGF reduces
PAR-2 protein level in hPSCs after 24 hrs, this TGF-β-
CTGF-PAR2 cascade occurs during the time period of 36
to 48 hr. Because IL-1β-induced PAR-2 expressed in hPSCs
might play a significantly important role in early phase of
OA, PAR2 repression by exogenous TGF-β or other agents
might be an ideal therapeutic target to prevent OA from
progression.
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